Fu Zheng, Lu Rong, Jia Jing, Zhao Lan, Ma Rui, Lv Jun-Qiang, Li Xiao-Lei, Chen Li-Juan, Zhang Hua-Li, Wang Li, Yao Zhi
Department of Immunology, Tianjin Medical University bPharmaped Research & Development (Shenzhen) Limited, Guangdong, PRC.
Anticancer Drugs. 2007 Apr;18(4):467-70. doi: 10.1097/CAD.0b013e328017766a.
The tripeptide tyroservatide (tyrosyl-seryl-valine, pTyr-Ser-Val-NH2) has been shown to have antitumor effects on experimental hepatocarcinoma. This study aimed to observe the effects of tyroservatide on other five human carcinomas: A549 (nonsmall cell lung carcinoma), BGC-823 (gastric cancer), MCF-7 (breast cancer), K562 (leukemia), A375 (melanoma) and two murine cancers: Lewis lung cancer and B16 (melanoma) in vivo. In vivo nude mice bearing xenografts of five different human tumors or C57BL/6 mice bearing xenografts of two different murine tumors were given daily intraperitoneal injections of tyroservatide or saline as controls, after tumor implantation. The inhibition of xenografts was determined by calculating the tumor volume and measuring tumor weight. Tyroservatide could significantly inhibit the growth of human lung carcinoma A549, human leukemia K562 and human melanoma A375 in nude mice (P<0.05). In addition, tyroservatide significantly inhibited the subcutaneous tumor growth of Lewis lung carcinoma and B16 melanoma (P<0.05). Tyroservatide, however, could not significantly suppress xenografts of BGC-823 and MCF-7 in nude mice (P>0.05). The results obtained indicate that tyroservatide exhibits different effects on different tumors, which will provide clinical applications guidance of tyroservatide as an anticancer drug.
三肽酪丝缬肽（酪氨酸-丝氨酸-缬氨酸，pTyr-Ser-Val-NH2）已被证明对实验性肝癌具有抗肿瘤作用。本研究旨在观察酪丝缬肽对另外五种人类癌症的影响：A549（非小细胞肺癌）、BGC-823（胃癌）、MCF-7（乳腺癌）、K562（白血病）、A375（黑色素瘤）以及两种小鼠癌症：Lewis肺癌和B16（黑色素瘤）的体内作用。在肿瘤植入后，给携带五种不同人类肿瘤异种移植瘤的裸鼠或携带两种不同小鼠肿瘤异种移植瘤的C57BL/6小鼠每日腹腔注射酪丝缬肽或作为对照的生理盐水。通过计算肿瘤体积和测量肿瘤重量来确定对异种移植瘤的抑制作用。酪丝缬肽可显著抑制裸鼠体内人类肺癌A549、人类白血病K562和人类黑色素瘤A375的生长（P<0.05）。此外，酪丝缬肽显著抑制Lewis肺癌和B16黑色素瘤的皮下肿瘤生长（P<0.05）。然而，酪丝缬肽不能显著抑制裸鼠体内BGC-823和MCF-7的异种移植瘤生长（P>0.05）。所得结果表明，酪丝缬肽对不同肿瘤表现出不同的作用，这将为酪丝缬肽作为抗癌药物的临床应用提供指导。
